Rice Hall James & Associates’s Eli Lilly LLY Stock Holding History

Rice Hall James & Associates’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Sell	1,615 -75	-4%	-$76K	0.08%	184
2025 Q4	$1.82M	Hold	1,690	–	–	0.1%	169
2025 Q3	$1.29M	Hold	1,690	–	–	0.07%	190
2025 Q2	$1.32M	Hold	1,690	–	–	0.07%	188
2025 Q1	$1.4M	Hold	1,690	–	–	0.08%	185
2024 Q4	$1.3M	Hold	1,690	–	–	0.07%	193
2024 Q3	$1.5M	Sell	1,690 -150	-8%	-$135K	0.08%	190
2024 Q2	$1.67M	Hold	1,840	–	–	0.1%	176
2024 Q1	$1.43M	Sell	1,840 -50	-3%	-$35.6K	0.08%	192
2023 Q4	$1.1M	Hold	1,890	–	–	0.06%	213
2023 Q3	$1.02M	Sell	1,890 -50	-3%	-$25.8K	0.06%	204
2023 Q2	$910K	Sell	1,940 -50	-3%	-$21K	0.05%	221
2023 Q1	$683K	Sell	1,990 -150	-7%	-$50.6K	0.04%	239
2022 Q4	$783K	Hold	2,140	–	–	0.04%	237
2022 Q3	$692K	Hold	2,140	–	–	0.04%	240
2022 Q2	$694K	Sell	2,140 -150	-7%	-$45K	0.03%	236
2022 Q1	$656K	Sell	2,290 -100	-4%	-$25.7K	0.03%	247
2021 Q4	$660K	Hold	2,390	–	–	0.02%	250
2021 Q3	$552K	Hold	2,390	–	–	0.02%	255
2021 Q2	$549K	Sell	2,390 -100	-4%	-$20.1K	0.02%	257
2021 Q1	$465K	Hold	2,490	–	–	0.02%	261
2020 Q4	$420K	Hold	2,490	–	–	0.01%	262
2020 Q3	$369K	Hold	2,490	–	–	0.01%	251
2020 Q2	$409K	Hold	2,490	–	–	0.02%	248
2020 Q1	$345K	Hold	2,490	–	–	0.02%	251
2019 Q4	$327K	Hold	2,490	–	–	0.01%	254
2019 Q3	$278K	Hold	2,490	–	–	0.01%	261
2019 Q2	$276K	Hold	2,490	–	–	0.01%	267
2019 Q1	$323K	Hold	2,490	–	–	0.01%	278
2018 Q4	$288K	Hold	2,490	–	–	0.01%	279
2018 Q3	$267K	Hold	2,490	–	–	0.01%	289
2018 Q2	$212K	Buy	+2,490	New	+$205K	0.01%	291
2018 Q1	–	Sell	-2,490	Closed	-$210K	–	300
2017 Q4	$210K	Hold	2,490	–	–	0.01%	294
2017 Q3	$213K	Hold	2,490	–	–	0.01%	283
2017 Q2	$205K	Hold	2,490	–	–	0.01%	285
2017 Q1	$209K	Buy	+2,490	New	+$199K	0.01%	290
2016 Q1	–	Sell	-2,940	Closed	-$248K	–	303
2015 Q4	$248K	Hold	2,940	–	–	0.01%	290
2015 Q3	$246K	Hold	2,940	–	–	0.02%	288
2015 Q2	$245K	Hold	2,940	–	–	0.01%	296
2015 Q1	$214K	Sell	2,940 -310	-10%	-$22.1K	0.01%	305
2014 Q4	$224K	Sell	3,250 -300	-8%	-$20.3K	0.01%	294
2014 Q3	$230K	Hold	3,550	–	–	0.02%	285
2014 Q2	$221K	Sell	3,550 -100	-3%	-$5.97K	0.01%	292
2014 Q1	$215K	Sell	3,650 -400	-10%	-$22.3K	0.02%	292
2013 Q4	$207K	Hold	4,050	–	–	0.01%	292
2013 Q3	$204K	Sell	4,050 -450	-10%	-$23.6K	0.02%	269
2013 Q2	$221K	Buy	+4,500	New	+$245K	0.02%	264

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Rice Hall James & Associates's LLY Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Eli Lilly (LLY) stake by 4.4% in Q1 2026, selling an estimated $76K and leaving 1,615 shares worth $1.49M. The position accounts for 0.08% of the portfolio, ranked #184.

Rice Hall James & Associates first reported a position in LLY in Q2 2013 and has held it in 47 quarters since. The position peaked at $1.82M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Rice Hall James & Associates held 1,615 shares of Eli Lilly worth $1.49M as of Q1 2026.
Rice Hall James & Associates sold 75 Eli Lilly shares in Q1 2026, an estimated $76K.
Eli Lilly made up 0.08% of Rice Hall James & Associates's portfolio in Q1 2026, its #184 holding.
Rice Hall James & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 47 quarters since.
Rice Hall James & Associates's Eli Lilly position peaked at $1.82M in Q4 2025.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.